Observational Study
Copyright ©The Author(s) 2021.
World J Clin Oncol. Jan 24, 2021; 12(1): 13-30
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.13
Figure 13
Figure 13  Protein expression of cytokeratin-19, CD45, and cyclin E in circulating tumor cells of a breast-brain metastatic patient. Circulating tumor cells (CTCs) in patient 17 with: A: DAPI (4′,6-diamidino-2-phenylindole)/cytokeratin-19 (CK-19) [highest/positive protein expression (PE)]; B: DAPI/CD45 (negative PE); C: DAPI/cyclin E (positive PE: Partial at left clone of cells); D, E and F: Conjugated cells with CK-19, CD45, and cyclin E, respectively. Harmonic PE between CK-19 and cyclin E in the clone of CTCs at left side of image in patient 17. Arrows indicate the diverse expression of three proteins.